Published in Blood on August 15, 1993
Inflammation and Alzheimer's disease. Neurobiol Aging (2000) 12.56
Interleukin-6-type cytokine signalling through the gp130/Jak/STAT pathway. Biochem J (1998) 7.15
Interleukin-6 in aging and chronic disease: a magnificent pathway. J Gerontol A Biol Sci Med Sci (2006) 2.85
Soluble receptors for cytokines and growth factors: generation and biological function. Biochem J (1994) 2.83
IL-6 trans-signaling via the soluble IL-6 receptor: importance for the pro-inflammatory activities of IL-6. Int J Biol Sci (2012) 2.15
IL-6 as a keystone cytokine in health and disease. Nat Immunol (2015) 2.14
Continuous activation of gp130, a signal-transducing receptor component for interleukin 6-related cytokines, causes myocardial hypertrophy in mice. Proc Natl Acad Sci U S A (1995) 2.05
Interleukin-6, a major cytokine in the central nervous system. Int J Biol Sci (2012) 2.01
The role of inflammatory and anti-inflammatory cytokines in the pathogenesis of osteoarthritis. Mediators Inflamm (2014) 1.76
Negative regulation of signaling by a soluble form of toll-like receptor 9. Eur J Immunol (2011) 1.66
Interleukin-6 and its receptor: from bench to bedside. Med Microbiol Immunol (2006) 1.65
The function of the soluble interleukin 6 (IL-6) receptor in vivo: sensitization of human soluble IL-6 receptor transgenic mice towards IL-6 and prolongation of the plasma half-life of IL-6. J Exp Med (1996) 1.65
Interleukin-6: structure-function relationships. Protein Sci (1997) 1.59
Evidence for altered activity of the IL-6 pathway in chronic rhinosinusitis with nasal polyps. J Allergy Clin Immunol (2010) 1.42
The roles of interleukin-6 in the pathogenesis of rheumatoid arthritis. Arthritis (2011) 1.33
Interleukin 6 and liver regeneration. Gut (2000) 1.32
c-Cbl-dependent monoubiquitination and lysosomal degradation of gp130. Mol Cell Biol (2008) 1.31
IL-6 in inflammation, immunity, and disease. Cold Spring Harb Perspect Biol (2014) 1.27
Ciliary neurotropic factor, interleukin 11, leukemia inhibitory factor, and oncostatin M are growth factors for human myeloma cell lines using the interleukin 6 signal transducer gp130. J Exp Med (1994) 1.22
Extramedullary expansion of hematopoietic progenitor cells in interleukin (IL)-6-sIL-6R double transgenic mice. J Exp Med (1997) 1.13
The role of interleukin-6 in the failing heart. Heart Fail Rev (2001) 1.10
Structure of the extracellular domains of the human interleukin-6 receptor alpha -chain. Proc Natl Acad Sci U S A (2002) 1.04
The soluble interleukin-6 receptor is a mediator of hematopoietic and skeletal actions of parathyroid hormone. J Biol Chem (2013) 1.00
Mediation of interleukin-11-dependent biological responses by a soluble form of the interleukin-11 receptor. Biochem J (1996) 0.99
Cytokine profiles in localized scleroderma and relationship to clinical features. Cytokine (2011) 0.98
N-linked glycosylation is essential for the stability but not the signaling function of the interleukin-6 signal transducer glycoprotein 130. J Biol Chem (2009) 0.98
Profile of soluble cytokine receptors in Crohn's disease. Gut (2005) 0.97
Mode of action of interleukin-6 on mature osteoclasts. Novel interactions with extracellular Ca2+ sensing in the regulation of osteoclastic bone resorption. J Cell Biol (1998) 0.96
The relationship between interleukin-6 and C-reactive protein in patients with benign and malignant prostate disease. Br J Cancer (2004) 0.95
Cloning of novel soluble gp130 and detection of its neutralizing autoantibodies in rheumatoid arthritis. J Clin Invest (2000) 0.92
Stressor-dependent Alterations in Glycoprotein 130: Implications for Glial Cell Reactivity, Cytokine Signaling and Ganglion Cell Health in Glaucoma. J Clin Exp Ophthalmol (2013) 0.90
Viral interleukin-6: role in Kaposi's sarcoma-associated herpesvirus: associated malignancies. J Interferon Cytokine Res (2011) 0.89
Tocilizumab for the treatment of rheumatoid arthritis and other systemic autoimmune diseases: current perspectives and future directions. Int J Rheumatol (2012) 0.89
Update on Targets of Biologic Therapies for Rheumatoid Arthritis. Curr Rheumatol Rev (2008) 0.89
Loss of tumoral expression of soluble IL-6 receptor is associated with disease progression in colorectal cancer. Br J Cancer (2010) 0.89
Definition and characterization of an inhibitor for interleukin-31. J Biol Chem (2010) 0.88
Serum soluble glycoprotein 130 concentration is inversely related to insulin sensitivity in women with polycystic ovary syndrome. Diabetes (2010) 0.86
IL-6 trans-signaling system in intra-amniotic inflammation, preterm birth, and preterm premature rupture of the membranes. J Immunol (2011) 0.85
IL-6 in diabetes and cardiovascular complications. Br J Pharmacol (2014) 0.85
Pattern of interleukin-6 receptor complex immunoreactivity between cortical regions of rapid autopsy normal and Alzheimer's disease brain. Eur Arch Psychiatry Clin Neurosci (2004) 0.83
A form of circulating interleukin-6 receptor component soluble gp130 as a potential interleukin-6 inhibitor in inflammatory bowel disease. Clin Exp Immunol (2006) 0.82
An inhibitor of interleukin-6 trans-signalling, sgp130, contributes to impaired acute phase response in human chronic liver disease. Clin Exp Immunol (2009) 0.82
High circulating levels of biologically inactive IL-6/SIL-6 receptor complexes in systemic juvenile idiopathic arthritis: evidence for serum factors interfering with the binding to gp130. Clin Exp Immunol (2003) 0.82
Interleukin-6: a new therapeutic target in systemic sclerosis? Clin Transl Immunology (2013) 0.81
A multiscale model of interleukin-6-mediated immune regulation in Crohn's disease and its application in drug discovery and development. CPT Pharmacometrics Syst Pharmacol (2014) 0.81
Elevated maternal soluble Gp130 and IL-6 levels and reduced Gp130 and SOCS-3 expressions in women complicated with preeclampsia. Hypertension (2010) 0.80
Selected cytokine pathways in rheumatoid arthritis. Semin Immunopathol (2017) 0.80
The role of interleukin-6 signalling and its therapeutic blockage in skewing the T cell balance in rheumatoid arthritis. Clin Exp Immunol (2017) 0.79
SOCS3 modulates interleukin-6R signaling preference in dermal fibroblasts. J Interferon Cytokine Res (2012) 0.78
Different Soluble Forms of the Interleukin-6 Family Signal Transducer gp130 Fine-tune the Blockade of Interleukin-6 Trans-signaling. J Biol Chem (2016) 0.78
Interleukin-6 Signaling Pathway and Its Role in Kidney Disease: An Update. Front Immunol (2017) 0.77
Alternative intronic polyadenylation generates the interleukin-6 trans-signaling inhibitor sgp130-E10. J Biol Chem (2014) 0.77
Generation of Soluble Interleukin-11 and Interleukin-6 Receptors: A Crucial Function for Proteases during Inflammation. Mediators Inflamm (2016) 0.77
Influence of humanized anti-IL-6R antibody, tocilizumab on the activity of soluble gp130, natural inhibitor of IL-6 signaling. Rheumatol Int (2008) 0.77
Mechanisms of immunomodulation by mammalian and viral decoy receptors: insights from structures. Nat Rev Immunol (2016) 0.76
SheddomeDB: the ectodomain shedding database for membrane-bound shed markers. BMC Bioinformatics (2017) 0.75
Functional annotation of a full-length mouse cDNA collection. Nature (2001) 23.61
Targeted disruption of Cbfa1 results in a complete lack of bone formation owing to maturational arrest of osteoblasts. Cell (1997) 18.91
Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis. Science (1997) 15.48
Requisite role of angiopoietin-1, a ligand for the TIE2 receptor, during embryonic angiogenesis. Cell (1996) 13.95
Identification of ubiquitin ligases required for skeletal muscle atrophy. Science (2001) 12.98
Akt/mTOR pathway is a crucial regulator of skeletal muscle hypertrophy and can prevent muscle atrophy in vivo. Nat Cell Biol (2001) 10.85
Defects of B-cell lymphopoiesis and bone-marrow myelopoiesis in mice lacking the CXC chemokine PBSF/SDF-1. Nature (1996) 10.67
Complementary DNA for a novel human interleukin (BSF-2) that induces B lymphocytes to produce immunoglobulin. Nature (1986) 9.63
ERKs: a family of protein-serine/threonine kinases that are activated and tyrosine phosphorylated in response to insulin and NGF. Cell (1991) 9.54
Vessel cooption, regression, and growth in tumors mediated by angiopoietins and VEGF. Science (1999) 9.18
The genome of the social amoeba Dictyostelium discoideum. Nature (2005) 9.18
A nuclear factor for IL-6 expression (NF-IL6) is a member of a C/EBP family. EMBO J (1990) 9.17
Isolation of angiopoietin-1, a ligand for the TIE2 receptor, by secretion-trap expression cloning. Cell (1996) 9.10
Impaired immune and acute-phase responses in interleukin-6-deficient mice. Nature (1994) 8.85
Interaction of tyrosine-based sorting signals with clathrin-associated proteins. Science (1995) 7.77
Impaired B-lymphopoiesis, myelopoiesis, and derailed cerebellar neuron migration in CXCR4- and SDF-1-deficient mice. Proc Natl Acad Sci U S A (1998) 7.69
The chemokine receptor CXCR4 is essential for vascularization of the gastrointestinal tract. Nature (1998) 7.38
Targeted disruption of the mouse Stat3 gene leads to early embryonic lethality. Proc Natl Acad Sci U S A (1997) 7.08
Leakage-resistant blood vessels in mice transgenically overexpressing angiopoietin-1. Science (1999) 6.96
Human catechol-O-methyltransferase pharmacogenetics: description of a functional polymorphism and its potential application to neuropsychiatric disorders. Pharmacogenetics (1996) 6.83
Mediation of IGF-1-induced skeletal myotube hypertrophy by PI(3)K/Akt/mTOR and PI(3)K/Akt/GSK3 pathways. Nat Cell Biol (2001) 6.71
Ordered rearrangement of immunoglobulin heavy chain variable region segments. EMBO J (1984) 6.67
Similarity of protein encoded by the human c-erb-B-2 gene to epidermal growth factor receptor. Nature (1986) 6.67
Essential role of Stat6 in IL-4 signalling. Nature (1996) 6.56
Essential role for oncogenic Ras in tumour maintenance. Nature (1999) 6.51
Molecular cloning of APRF, a novel IFN-stimulated gene factor 3 p91-related transcription factor involved in the gp130-mediated signaling pathway. Cell (1994) 6.45
Developmentally controlled and tissue-specific expression of unrearranged VH gene segments. Cell (1985) 6.21
The immune responses in CD40-deficient mice: impaired immunoglobulin class switching and germinal center formation. Immunity (1994) 6.18
Structure and function of a new STAT-induced STAT inhibitor. Nature (1997) 6.02
Green revolution: a mutant gibberellin-synthesis gene in rice. Nature (2002) 5.84
Preferential utilization of the most JH-proximal VH gene segments in pre-B-cell lines. Nature (1984) 5.75
Interleukin-6 triggers the association of its receptor with a possible signal transducer, gp130. Cell (1989) 5.72
Epstein-Barr virus nuclear antigen 2 specifically induces expression of the B-cell activation antigen CD23. Proc Natl Acad Sci U S A (1987) 5.68
Autocrine generation and requirement of BSF-2/IL-6 for human multiple myelomas. Nature (1988) 5.60
Angiopoietin-1 protects the adult vasculature against plasma leakage. Nat Med (2000) 5.58
Fcgamma receptor-mediated induction of dendritic cell maturation and major histocompatibility complex class I-restricted antigen presentation after immune complex internalization. J Exp Med (1999) 5.55
Gp130 and the interleukin-6 family of cytokines. Annu Rev Immunol (1997) 5.38
Double-blind randomized controlled clinical trial of the interleukin-6 receptor antagonist, tocilizumab, in European patients with rheumatoid arthritis who had an incomplete response to methotrexate. Arthritis Rheum (2006) 5.20
Biological and clinical aspects of interleukin 6. Immunol Today (1990) 5.17
Biology of multifunctional cytokines: IL 6 and related molecules (IL 1 and TNF). FASEB J (1990) 5.16
Cytokine signal transduction. Cell (1994) 5.14
Molecular cloning and expression of an IL-6 signal transducer, gp130. Cell (1990) 5.06
Cloning and expression of the human interleukin-6 (BSF-2/IFN beta 2) receptor. Science (1988) 4.93
Choice of STATs and other substrates specified by modular tyrosine-based motifs in cytokine receptors. Science (1995) 4.90
Stat3 activation is responsible for IL-6-dependent T cell proliferation through preventing apoptosis: generation and characterization of T cell-specific Stat3-deficient mice. J Immunol (1998) 4.74
Defective NK cell activity and Th1 response in IL-18-deficient mice. Immunity (1998) 4.70
Synergistic signaling in fetal brain by STAT3-Smad1 complex bridged by p300. Science (1999) 4.69
An insulin-stimulated protein kinase similar to yeast kinases involved in cell cycle control. Science (1990) 4.63
Interleukin-6 family of cytokines and gp130. Blood (1995) 4.52
Defective adipocyte differentiation in mice lacking the C/EBPbeta and/or C/EBPdelta gene. EMBO J (1997) 4.51
Genetic analysis of novel avian A(H7N9) influenza viruses isolated from patients in China, February to April 2013. Euro Surveill (2013) 4.44
Targeted disruption of the NF-IL6 gene discloses its essential role in bacteria killing and tumor cytotoxicity by macrophages. Cell (1995) 4.34
The essential role of B cell stimulatory factor 2 (BSF-2/IL-6) for the terminal differentiation of B cells. J Exp Med (1988) 4.31
Delta-like ligand 4 (Dll4) is induced by VEGF as a negative regulator of angiogenic sprouting. Proc Natl Acad Sci U S A (2007) 4.27
Regulation of gliogenesis in the central nervous system by the JAK-STAT signaling pathway. Science (1997) 4.26
Molecular cloning and structure of a pre-B-cell growth-stimulating factor. Proc Natl Acad Sci U S A (1994) 4.25
Association of transcription factor APRF and protein kinase Jak1 with the interleukin-6 signal transducer gp130. Science (1994) 4.24
Transcription factors NF-IL6 and NF-kappa B synergistically activate transcription of the inflammatory cytokines, interleukin 6 and interleukin 8. Proc Natl Acad Sci U S A (1993) 4.23
Development of the primary antibody repertoire. Science (1987) 4.19
Insertion of N regions into heavy-chain genes is correlated with expression of terminal deoxytransferase in B cells. Nature (1984) 4.18
Eph receptors and ligands comprise two major specificity subclasses and are reciprocally compartmentalized during embryogenesis. Neuron (1996) 4.12
Differentiation stage-specific inhibition of the Raf-MEK-ERK pathway by Akt. Science (1999) 4.10
Regulation of the assembly and expression of variable-region genes. Annu Rev Immunol (1986) 4.09
Interleukin-6 in biology and medicine. Adv Immunol (1993) 4.06
IgG1 plasmacytosis in interleukin 6 transgenic mice. Proc Natl Acad Sci U S A (1989) 4.03
Infection with HIV is associated with elevated IL-6 levels and production. J Immunol (1990) 3.89
Myogenic cells derived from rat bone marrow mesenchymal stem cells exposed to 5-azacytidine. Muscle Nerve (1995) 3.84
The receptor tyrosine kinase MuSK is required for neuromuscular junction formation in vivo. Cell (1996) 3.81
Tie2 receptor ligands, angiopoietin-1 and angiopoietin-2, modulate VEGF-induced postnatal neovascularization. Circ Res (1998) 3.79
Recombination between immunoglobulin variable region gene segments is enhanced by transcription. Nature (1987) 3.74
Increased vascularization in mice overexpressing angiopoietin-1. Science (1998) 3.67
Regulation of genome rearrangement events during lymphocyte differentiation. Immunol Rev (1986) 3.65
Structure and expression of human B cell stimulatory factor-2 (BSF-2/IL-6) gene. EMBO J (1987) 3.64
Phosphorylation at threonine-235 by a ras-dependent mitogen-activated protein kinase cascade is essential for transcription factor NF-IL6. Proc Natl Acad Sci U S A (1993) 3.59
Failure to synthesize the T cell CD3-zeta chain: structure and function of a partial T cell receptor complex. Cell (1988) 3.59
Differential expression of myc family genes during murine development. Nature (1986) 3.57
Ligands for EPH-related receptor tyrosine kinases that require membrane attachment or clustering for activity. Science (1994) 3.53
Interleukin-6 and its receptor: a paradigm for cytokines. Science (1992) 3.51
Introduced T cell receptor variable region gene segments recombine in pre-B cells: evidence that B and T cells use a common recombinase. Cell (1986) 3.51
Purification to homogeneity and characterization of human B-cell differentiation factor (BCDF or BSFp-2). Proc Natl Acad Sci U S A (1985) 3.46
New model of tumor angiogenesis: dynamic balance between vessel regression and growth mediated by angiopoietins and VEGF. Oncogene (1999) 3.45
Cardiovascular anomaly, impaired actin bundling and resistance to Src-induced transformation in mice lacking p130Cas. Nat Genet (1998) 3.38
Growth factors acting via endothelial cell-specific receptor tyrosine kinases: VEGFs, angiopoietins, and ephrins in vascular development. Genes Dev (1999) 3.35
In vivo effects of anti-asialo GM1. I. Reduction of NK activity and enhancement of transplanted tumor growth in nude mice. J Immunol (1981) 3.34
Maturational disturbance of chondrocytes in Cbfa1-deficient mice. Dev Dyn (1999) 3.33
Microtubule-associated protein 2 kinases, ERK1 and ERK2, undergo autophosphorylation on both tyrosine and threonine residues: implications for their mechanism of activation. Proc Natl Acad Sci U S A (1991) 3.31
Critical cytoplasmic region of the interleukin 6 signal transducer gp130 is conserved in the cytokine receptor family. Proc Natl Acad Sci U S A (1991) 3.31